Ftse Mib
37.109,73
-0,03%
DAX
21.925,63
0,06%
S&P 500
6.083,57
0,36%
NASDAQ
19.791,99
0,51%
Bitcoin
96.890,63
0,33%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Hoth Therapeutics Inc (HOTH) Hoth Therapeutics Inc (HOTH) Notizie

Hoth Therapeutics Inc

HOTH
1,20
0,00 (0,00%)
07 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/1/202522:15EDGAR2Form 8-K - Current report
24/1/202514:29PRNUSHoth Therapeutics Regains Compliance with Nasdaq Listing..
21/1/202514:29PRNUSHoth Therapeutics Expands Intellectual Property Portfolio..
17/1/202514:29PRNUSHoth Therapeutics to Attend Sequire Investor Summit January..
15/1/202522:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202519:27PRNUSHoth Therapeutics Responds to Market Rumors and Shareholder..
07/1/202518:35APSShares Of This Micro Cap More Than Doubled Today
07/1/202514:29PRNUSHoth Therapeutics Achieves Breakthrough in Phase 2a Trial:..
26/12/202413:58PRNUSHoth Therapeutics Enters Partnership with the Department of..
02/12/202422:15EDGAR2Form 8-K - Current report
20/11/202414:30EDGAR2Form 8-K - Current report
20/11/202413:38PRNUSHoth Therapeutics Board of Directors Approves Bitcoin as..
12/11/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202423:30EDGAR2Form 8-K - Current report
01/11/202421:15EDGAR2Form 8-K - Current report
29/10/202417:43PRNUSHoth Therapeutics Announces Update on Cancer Therapeutic..
15/10/202412:38PRNUSHoth Therapeutics Awarded Key US Patent for Groundbreaking..
17/9/202413:57PRNUSHoth Therapeutics Announces Promising Preclinical Results..
05/9/202416:32PRNUSHoth Therapeutics Announces Expansion of Clinical Sites for..
05/9/202414:03PRNUSHoth Therapeutics Announces Positive Data from..
21/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202422:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/8/202414:04PRNUSHoth Therapeutics and Aronnax Inc. Enter Master Services..
09/8/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202422:15EDGAR2Form 8-K - Current report
24/7/202416:30APSMicro Cap Already Off To The Races At The Bell
24/7/202412:30PRNUSHoth Therapeutics Partners with LTS Therapy Systems to..
16/7/202414:31PRNUSHoth Therapeutics Expands Clinical Trial for Cancer Patients
18/6/202412:15EDGAR2Form ARS - Annual Report to Security Holders
18/6/202412:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/6/202412:07EDGAR2Form DEF 14A - Other definitive proxy statements
17/6/202422:41EDGAR2Form 8-K - Current report
10/6/202414:11PRNUSHoth Therapeutics Announces Joint Development Agreement with..
14/5/202422:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/5/202414:00PRNUSHoth Therapeutics to Attend EF Hutton Annual Global..
27/3/202419:00PRNUSHoth Therapeutics Announces Exercise of Warrants for $4.2..
27/3/202413:27PRNUSHoth Therapeutics' Wholly Owned Subsidiary Merveille.ai,..
19/3/202413:21PRNUSHoth Therapeutics Announces Positive Data In Completed Study..
29/2/202414:38PRNUSHoth Therapeutics Retains Venable LLP to Expand Its Patent..
26/2/202414:11PRNUSHoth Therapeutics Engages Altasciences to Perform Key Study..
13/2/202417:45PRNUSHoth Therapeutics to Attend BIO CEO and Investor Conference,..
Apertura: Min: Max:
Chiusura: 1,20

La tua Cronologia

NASDAQ
HOTH
Hoth Therapeutics
BOV
ICBIO
ICBIO
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci